HER2 Lung Cancer Explained: Overexpression, Amplification & Exon 20 Mutation | Dr. Concannon | Pt 1

n lung cancer, HER2 can mean different things.In Part 1 of our HER2-driven lung cancer series, Leah Phillips sits down with thoracic medical oncologist Dr. Kyle Concannon (UC Health, University of Colorado) to cover the basics: what a HER2 alteration actually is, the difference between overexpression, amplification, and the exon 20 insertion mutation, why the type matters for treatment, and why next-generation sequencing at diagnosis is non-negotiable.This is Part 1 of 3. Parts 2 and 3 cover treatment and monitoring, then resistance and emerging research.About Dr. Kyle Concannon: Assistant Professor of Medicine-Medical Oncology at the University of Colorado and a thoracic medical oncologist at UCHealth University of Colorado Hospital. Trained as a physician-scientist at MD Anderson, his lab studies why oncogene-driven lung cancers (EGFR, HER2, ALK, ROS1) stop responding to therapy and how to overcome that resistance. He also co-hosts The  @crackingcancer podcast https://som.cuanschutz.edu/Profiles/Faculty/Profile/40545This series is proudly sponsored by Boehringer Ingelheim.This is educational content. Not medical advice. Always talk to your own care team about your specific situation.